Cytosorbents (CTSO) FCF Margin Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,293.00 |
| Dec 31, 2025 | -4,322.00 |
| Sep 30, 2025 | 597.00 |
| Jun 30, 2025 | -3,504.00 |
| Mar 31, 2025 | -18.00 |
| Dec 31, 2024 | 3,106.00 |
| Sep 30, 2024 | 5,716.00 |
| Jun 30, 2024 | -103.00 |
| Mar 31, 2024 | 3,303.00 |
| Dec 31, 2023 | -2,760.00 |
| Sep 30, 2023 | -1,434.00 |
| Jun 30, 2023 | -1,565.00 |
| Mar 31, 2023 | 1,679.00 |
| Dec 31, 2022 | -10,105.00 |
| Sep 30, 2022 | 4,429.00 |
| Jun 30, 2022 | -7,385.00 |
| Mar 31, 2022 | -5,197.00 |
| Dec 31, 2021 | -5,019.00 |
| Sep 30, 2021 | 7,485.00 |
| Jun 30, 2021 | 6,583.00 |
| Mar 31, 2021 | 4,548.00 |
| Dec 31, 2020 | 12,226.00 |
| Sep 30, 2020 | 14,285.00 |
| Jun 30, 2020 | 29,772.00 |
| Mar 31, 2020 | 24,595.00 |
| Dec 31, 2019 | 18,934.00 |
| Sep 30, 2019 | 8,134.00 |
| Jun 30, 2019 | 9,242.00 |
| Mar 31, 2019 | -992.00 |
| Dec 31, 2018 | 1,043.00 |
| Sep 30, 2018 | 3,698.00 |
| Jun 30, 2018 | 75,478.00 |
| Mar 31, 2018 | 41,122.00 |
| Dec 31, 2017 | 87,109.00 |
| Sep 30, 2017 | 457,376.00 |
| Jun 30, 2017 | 223,567.00 |
| Mar 31, 2017 | 206,898.00 |
| Dec 31, 2016 | 304,076.00 |